| Overall (n = 46) | WF at diagnosis WF +  (n = 10) | No WF at diagnosis WF− (n = 36) |
---|---|---|---|
BD-IPMN | 36 (78.3) | 5 (50.0) | 31 (86.1) |
MD-IPMN | 7 (15.2) | 3 (30.0) | 4 (11.1) |
MT-IPMN | 3 (6.5) | 2 (20.0) | 1 (2.8) |
Diagnosis confirmed by MRI and / or EUS | 43 (93.5) | 10 (100) | 3 (83.3) |
Diagnostic EUS-FNA | 13 (28.3) | 5 (50.0) | 8 (22.2) |
EUS-FNA during surveillance | 17 (37.0 | 6 (60.0) | 11 (30.6) |
Median follow-up time (IQR) [months] | 23 (27) | 21 (12.8) | 23 (27.5) |
Median time to progression (IQR) [months] | 11 (9) | 16 (5) | 9 (4) |
Progression during FU (appearance of new WF)1 | 11 (23.9) | 5 (50.0) | 6 (16.7) |
 Cyst size ≥ 3 cm | 2 | 0 | 2 |
 Cyst growth rate of ≥ 5 mm/2 years | 9 | 5 | 4 |
 Thickened or enhancing cyst walls | 4 | 1 | 3 |
 MPD-size ≥ 5 mm | 1 | 0 | 1 |
 High-grade dysplasia on EUS-FNA | 0 | 0 | 0 |
Surgery | 5 (10.9) | 2 (20.0) | 3 (8.3) |
 IPMN progression (rapid cyst growth) | 3 | 2 | 1 |
 Concomitant disease | 2 | 0 | 2 |
Surveillance status | Â | Â | Â |
 Active surveillance | 25 (54.4) | 4 (40.0) | 21 (58.3) |
 FU stopped (comorbidities) | 2 (4.3) | 1 (10.0) | 1 (2.8) |
 FU stopped (death) | 1 (2.2) | 0 (0.0) | 1 (2.8) |
 FU stopped (regression, disease stability) | 2 (4.3) | 1 (10.0) | 1 (2.8) |
 Patient did not wish to continue FU | 9 (19.6) | 2 (20.0) | 7 (19.4) |
 Lost to follow-up | 2 (4.3) | 0 (0.0) | 2 (5.6) |